Amalia Ysabelle
Jul 25, 2017
•
Featured
Federal Circuit Finds Velcade Patent Not Obvious Under Lead Compound Analysis
In Millennium Pharmaceuticals, Inc. v. Sandoz, the Federal Circuit reversed the district court decision that invalidated one of the Orange Book-listed patents covering the anti-cancer drug Velcade. In so doing, the court explained that a novel product with unexpected advantageous properties is not obvious just because the process by which it was made might have been.
http://bit.ly/2vFGpKL